Business Context and Reporting Period
This Form 8-K Current Report was filed by LabStyle Innovations Corp. on April 5, 2013. The filing discloses the initial closing of a private placement offering of units to accredited investors. Note: The request metadata references "Dariohealth Corp.", but the filing text explicitly identifies the registrant as "LabStyle Innovations Corp."
Key Financial Metrics
- Gross Proceeds: $1,675,000 from the sale of 6.7 Units.
- Net Proceeds: Approximately $1,484,375 after deducting fees and expenses.
- Placement Agent Fees: $139,125 in cash and non-accountable allowance.
- Equity Issued: 670,000 shares of Common Stock.
- Warrants Issued to Investors: Rights to purchase 335,000 shares at $5.00 per share.
- Warrants Issued to Agent: Rights to purchase 67,000 shares at $2.50 and 33,500 shares at $5.00.
The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the capital raise via the private placement. The company entered into definitive subscription agreements with five accredited investors, resulting in an immediate increase in cash liquidity and an expansion of the company's capital structure through the issuance of new common stock and warrants.
Outlook, Risks, and Contingencies
- Registration Rights: The company is obligated to file a registration statement with the SEC following the final closing of the offering to cover the resale of the issued securities.
- Restrictions: The securities are unregistered and restricted under Rule 144; they cannot be resold absent registration or an applicable exemption.
- Offering Status: This report covers only the "Initial Closing." A final closing is anticipated to complete the offering.
Investor Verification Checklist
- Verify the final closing date and total aggregate proceeds of the offering.
- Confirm the filing of the registration statement for the resale of investor securities.
- Review the company's use of the net proceeds ($1.48M) in subsequent financial reports.
- Check for any dilution impact on existing shareholders from the 670,000 new shares and warrant exercises.